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Abstract. Vascular Endothelial Growth Factor (VEGF) pathway has emerged as one of the 
most important positive modulators of Angiogenesis, a central process implicated in 
tumour growth and metastatic dissemination. This led to the design and development of 
anti-VEGF monoclonal antibodies and small-molecule ATP-competitive VEGFR-
inhibitors. In this study, we describe the synthesis and the biological evaluation of novel 2-
aryl substituted benzothiopyrano-fused pyrimidines 1a-i, 2a-i and 3a-i. The ability of the 
compounds to target the Vascular Endothelial Growth Factor (VEGF) pathway was 
determined in vitro exploiting the compounds’ antiproliferative efficacy against HUVEC 
cells. The VEGFR-2 inhibition was confirmed by enzymatic assays on recombinant human 
kinase insert domain receptor (KDR), by cell-based phospho-VEGFR-2 inhibition assays, 
and by ex vivo rat aortic ring tests. The selectivity profile of the best performing derivatives 
belonging to series 2 was further explored combining modelling studies and additional 
assays in a panel of human cell lines and other kinases. 
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1. Introduction 
 
Angiogenesis is a physiological process that leads to the formation of new capillaries 
sprouting or splitting from pre-existing vessels, a requirement necessary for growth and 
proliferation of solid tumors. [1]. Accordingly, inhibition of this process may reduce 
vascularization, resulting in antitumor therapies that are supposed to be less toxic for 
chronic administration, in comparison with conventional chemotherapeutic treatments, and 
able to maximize the results, while suppressing tumour metastasis [2,3].  
The angiogenic process is orchestrated via the expression of a range of cell surface and 
intracellular proangiogenic factors, including the vascular endothelial growth factor 
(VEGF) family (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E).  The various members 
of the VEGF family have overlapping abilities to interact with a set of highly homologous 
tyrosine kinase receptors (TKRs): VEGFR-1 (Flt-1) and VEGFR-2 (human KDR or 
murine Flk-1), largely expressed in endothelial cells, and primarily involved in both 
physiological and pathological angiogenesis. [4,5]. Although the precise role of VEGFR-1 
function is still emerging, it seems to act primarily as a decoy receptor, modulating the 
availability of VEGF for VEGFR-2, which is the principal receptor, through which VEGF 
exerts its responses in endothelial cells.  
In tumour cells, VEGFR-2 is strongly autophosphorylated by increased expression of 
VEGFs and mediates a serial of mitogenic and survival downstream pathways, including 
MAPK, P13K or Akt, which are usually hyperactivated in several malignances [6-8].  
From the improved understanding of angiogenesis mechanisms in tumorigenesis, the 
therapeutic strategies blocking VEGF/VEGFR-2 signalling systems became a promising 
and well-validated approach for suppression of pathological neovascularisation and, 
consequently, for the treatment of both solid tumours and haematological malignancies [9, 
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10]. Agents currently developed against VEGF or its receptors include the humanized anti-
VEGF monoclonal antibody Bevacizumab, which targets extracellular VEGF.  By means 
of receptor-based virtual screening studies, a significant number of small molecules 
VEGFR-2 inhibitors, which compete with ATP binding in the catalytic domain of tyrosine 
kinase, has been developed, leading to the identification of several classes of VEGFR 
inhibitors, such as Semaxanib (SU5416), Vandetanib (ZD6474), Vatalanib (PTK787), and 
AAL993 (ZK260253), (Chart 1).  
 
 
 
Chart 1. Structures of VEGFR Tyrosine Kinase inhibitors. 
 
The most performing leads, designed as ATP competitive compounds, proved to firmly 
bind to the catalytic site of the proteins, exploiting hydrophobic interactions, strengthened 
by one or more hydrogen bonding groups, often heteroatoms. Moreover, other substituents, 
connected by different spacer chains, including amino and/or amide groups, can protrude 
toward two other distinct areas of the site: the so called “solvent accessible region” and 
“buried region” [11, 12].  
Among the wide series of thoroughly described chemical structures [13, 14], we drew our 
attention on those containing, as privileged moiety, a pyrimidine ring, either isolated or 
fused to form different heterocyclic structures, (Pyrrolo-pyrimidines, Pyrazolo-
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pyrimidines, Furo- and Thieno-pyrimidines, Pyrimido-pyrimidinones, Pyrido-pyrimidones) 
that have been reported as interesting VEGFR inhibitors (Chart 2).  
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Chart 2. VEGFR inhibitors containing both pendant or fused pyrimidines. 
 
The research program of our group has always been devoted to the preparation and the 
evaluation of polycyclic chromophores extensively studied as new antiproliferative agents 
[15-17]. In the last years, some studies on the benzothiopyranopyrimidine system gave rise 
to the disclosure of novel compounds endowed with interesting pharmacological properties 
[18,19]; in particular the benzothiopyranopyrimidine A (Chart 3) showed an appreciable 
cytotoxic activity on HL-60 cell line (GI50 = 7.15 M) [20].  
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Chart 3. Structures of benzothiopyranopyrimidines. 
 
Focusing on these results and moving from the structures of some reported anilino 
substituted pyrimidines [21], we designed the series of benzothiopyrano-fused pyrimidines 
of general formula I, (Chart 3), characterized by an aniline moiety inserted in the 2-
position of the tricyclic system. Moreover, with the aim to perform critical SAR studies 
and to confirm the role of the NH group, the analogue 2-benzylamino and 2-phenyl 
derivatives have been also synthesized. 
It was hypothesized that these new products might share the pharmacophoric requirements 
suitable for an anchoring to the ATP binding site, in particular the aniline NH group and 
the pyrimidine N1 and N3 atoms, that might be implicated in H-bonding interactions with 
critical residues of the catalytic cleft [13,14].  
The ability of the new benzothiopyrano-pyrimidines I to inhibit the kinase activity of the 
VEGFR-2 was determined by a biochemical assay. The effect of the compounds on 
viability of human umbilical vein endothelial cells (HUVECs) was evaluated by means of 
an inhibition growth assay. The capacity of the most interesting compounds to inhibit the 
enzyme catalyzed phosphorylation processes, in HUVECs, as well as the ability to 
interfere with the angiogenic process in vitro on rat aortic rings, has been assayed. The 
antiproliferative properties of all compounds have been further investigated on a panel of 
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human tumor cell lines, and the angio-kinase selectivity profile was assessed against a set 
of 11 human kinases. Finally, molecular docking calculations allowed clarifying at 
molecular level the interaction pattern established by the compounds with the KDR domain 
of VEGFR-2. 
 
2. Results and discussion 
 
2.1. Chemistry 
 
The synthetic procedure leading to the target 2-aryl-substituted-5H-benzothiopyrano 
[4,3-d]pyrimidine derivatives 1a-i, 2a-i and 3a-i takes advantage by the use as “synthetic 
tool” of the 7-substituted benzothiopyrane moiety, which was demonstrated to be a 
versatile intermediate [20].  
The 1,3-bielectrophile reactivity of the opportune intermediate 7-substituted-3-
dimethylaminomethylene derivatives 4a-c [20,22-24] in the reaction with the appropriate 
binucleophile amidines 5a-c or 6a-c in an ethanolic refluxing solution, in the presence of 
sodium ethoxide [25], allowed to easily obtain the desired 2-phenyl substituted pyrimidines 
1a-i and their benzylamino substituted analogues 3a-i, as reported in Scheme 1. P-
substituted benzamidine hydrochlorides 5b-c, even commercially available, were difficult 
to find; so they were obtained with good yields by reaction of the appropriate benzonitrile 
derivative with a methanol solution of sodium methoxide and ammonium chloride, as 
reported in literature [26-28]. The p-substituted benzylguanidines 6a-c were synthesized by 
condensation of methylthiopseudourea sulfate with the appropriate benzylamine in 
aqueous solution, following already described procedures [29-31].  
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Scheme 1. Reagents and conditions: i) MeONa, MeOH, NH4Cl; ii) methylthiopseudourea 
sulphate, H2O, r.t. for 7 hours, 100 °C for 16 hours; iii) EtONa, refluxing ethanol. 
 
The crude target compounds were obtained as unique products (tlc analysis) in good 
overall yields, and purified by crystallization. 
The preparation of compounds 2a-i was accomplished by means of a different synthetic 
route. [32] 3-Dimethylaminomethylene derivatives 4a-c were allowed to react with 
guanidine hydrochloride to obtain the 7-substituted-2-aminopyrimidino derivatives 7a-c, 
which, by reacting under nitrogen atmosphere with the appropriately p-substituted 
phenyliodide in anhydrous dioxane, in the presence of K2CO3, N,N'-
dimethylethylendiamine and CuI, afforded the crude target compounds 2a-i which were 
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purified by flash chromatography, using petroleum ether 60-80 °C/ethyl acetate 70:30 as 
the eluting system (Scheme 2).  
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Scheme 2. Reagents and conditions: i) guanidine hydrochloride, EtONa, refluxing ethanol; 
ii) p-substitutedphenyliodide, K2CO3, N,N'-dimethylethylendiamine, CuI, dioxane. 
 
The purity of the target compounds was assessed by TLC analysis and by physicochemical 
properties, analytical and 1H NMR and 13C NMR spectral data, which were in agreement 
with the proposed structures and with other previously reported results. (Experimental 
protocols for details).  
 
2.2. Biological evaluation 
2.2.1. KDR inhibition assay 
The ability of the new 2-aryl-substituted benzothiopyrano-pyrimidines 1a-i, 2a-i and 
3a-i in inhibiting the kinase activity of the VEGFR-2 was determined by a biochemical 
assay performed with a recombinant human kinase insert domain receptor (KDR), using 
Semaxanib (SU5414) as reference standard. Despite its moderate potency, Semaxanib 
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shows a useful selectivity in inhibiting VEGFR-1 and -2 tyrosine kinases and VEGF-
dependent endothelial proliferation, as compared with novel more potent but multitargeted 
receptor tyrosine kinase inhibitors, like Sunitinib or Sorafenib [33]. As reported in Table 1, 
listing activities expressed as inhibition percentage at 7 M concentration, the results 
obtained highlighted generally good to high values of KDR inhibition for the most part of 
the 2-anilino substituted derivatives (compounds of series 2), in some cases even higher 
with respect to that exerted by Semaxanib. Both the addition of a methylene spacer 
(compounds of series 3) and the deletion of the amino group (compounds of series 1) 
reduced the inhibitory efficacy against the target protein, thus clearly indicating a crucial 
role for the length of the side chain and the NH group. 
 
 
Table 1. KDR Enzyme Inhibitory Activity and HUVEC Cell Growth Inhibition of 
Derivatives 1a-i, 2a-i and 3a-i. 
S
NN
X
Z R
 
    %a IC50b (M) GI50c (M) 
Compd. Z X R KDR KDR HUVEC 
1a - H H 20  4.0 
1b - H OCH3 31  12 
1c - H Cl 20  11.3 
1d - OCH3 H 20  2.9 
1e - OCH3 OCH3 20  4.8 
1f - OCH3 Cl 20  >20 
1g - Cl H 20  2.3 
1h - Cl OCH3 41  4.7 
1i - Cl Cl 20  15.3 
2a NH H H 54 8.2 2.4 
2b NH H OCH3 67 2.7 0.45 
2c NH H Cl <20 >50 7.3 
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2d NH OCH3 H 35 >50 4.3 
2e NH OCH3 OCH3 39 17.5 0.74 
2f NH OCH3 Cl <20 >50 >20 
2g NH Cl H <20 >50 >20 
2h NH Cl OCH3 <20 >50 16.4 
2i NH Cl Cl 61 5.6 0.35 
3a NHCH2 H H 20  >20 
3b NHCH2 H OCH3 20  >20 
3c NHCH2 H Cl 20  12.3 
3d NHCH2 OCH3 H 20  >20 
3e  NHCH2 OCH3 OCH3 20  >20 
3f NHCH2 OCH3 Cl 20  >20 
3g NHCH2 Cl H 20  15.1 
3h NHCH2 Cl OCH3 35  12 
3i NHCH2 Cl Cl 20  17 
Semaxanib    40 12.9 13.6 
 
 
 
 
 
 
a Percentage of kinase inhibition obtained at 7 M of test compound. 
b IC50 values represent the concentration that induces the 50% reduction in enzyme activity. 
c GI50 values represent the concentration (M) of compound able to produce 50% cell death 
with respect to the control culture. 
 
Moreover, an important role of the substituents on both the chromophore and the pendant 
phenyl moiety, position 8 (X) and 4' (R), was observed. In the case of the 2-anilino-
substituted derivatives 2, when the distal phenyl ring is unsubstituted (2a, 2d, 2g), or bears 
a p-methoxy group (2b, 2e, 2h), the inhibition percentages progressively decrease when 
methoxy or, to a greater extent, chlorine substituents are present at 8-position of the 
chromophore. Conversely, when a pendant p-chloro phenyl group is present (2c, 2f, 2i) 
only the insertion of a chlorine in the 8-position, as in compound 2i, allowed the 
occurrence of inhibitory capacity. Accordingly, a significant inhibitory efficacy has 
displayed by compounds 2a, 2b, 2e and 2i; with 2b and 2i showing the highest percentage 
values in the whole subseries. 
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Within the series of the 2-phenyl (1a-i) or 2-benzylamino (3a-i) substituted derivatives, the 
8-chloro-4'-methoxy substituted analogues 1h and 3h turned out to be the most active 
inhibitors with percentage values lower or comparable to those of the reference drug. 
The activity of the best performing 2-anilino-substituted derivatives was also calculated as 
IC50 (Table 1). The results confirm for 2a, 2b, 2e and 2i an interesting capacity to inhibit 
the enzyme, with IC50 values ranging from 2.7 to 17.5 M, comparable (2e) or even lower 
(2a, 2b and 2i) with respect to that obtained for the reference compound. 
 
2.2.2. Evaluation on HUVEC cells 
The ability of new derivatives to inhibit the phosphorylation activity of VEGFR-2, 
prompted us to test their effect on human umbilical vein endothelial cells (HUVECs) 
growth by means of an in vitro assay. The results, expressed as GI50 values, are showed in 
Table 1, Semaxanib was used as reference compound. 
After a 72-h exposure, the ability to exert antiproliferative effects on HUVEC cells was 
shown by the majority of 2-phenyl substituted pyrimidines 1a-i showing GI50 values, in the 
micromolar range (from 2.3 to 15.3 M), comparable or lower to that of Semaxanib. The 
most part of 2-anilino pyrimidines 2a-i is able to exert a significant cytotoxicity and, 
interestingly inside this subseries, derivatives 2b, 2e and 2i show even submicromolar GI50 
values (0.35-0.74 M). In contrast, the 2-benzylamino substituted derivatives 3a-i always 
exhibited low or null cytotoxic capacities in these cells. Significantly, by comparing the 
antiproliferative effects exerted by analogous compounds, bearing the same aryl side 
group, a certain role seems to be played by the substituents in position 8 (X) and 4' (R). 
Within the sub-series 1a-i, the most active compounds are 1a, 1d, 1g followed by 1b, 1e, 
1h, bearing the unsubstituted (R = H) and the methoxy substituted (R = OCH3) pendant 
phenyl group, respectively. Conversely, the presence of a chlorine (R = Cl), as in 
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compounds 1c, 1f and 1i, generally reduces the activity. As regards the role of the X group 
in the 8-position, a similar profile is displayed within each group of analogues, since the 
introduction of methoxy (1d, 1e versus 1a, 1b) or chlorine (1g, 1h versus 1a, 1b) increases 
cytotoxic ability, but in the p-chloro subseries (1f, 1i versus 1c). The nature of the 
substituents X and R also modulates the antiproliferative effects in the group of 2-anilino 
substituted pyrimidines 2a-i. Actually, cytotoxic potency is usually enhanced by the 
insertion of a methoxy electron donating group on the phenyl ring (R = OCH3, compounds 
2b, 2e versus 2a, 2d) or it is lowered by a chlorine (R = Cl, compounds 2c, 2f versus 2a, 
2d). The presence of the halogen in the 8-position (X = Cl) on the heterocyclic scaffold 
gives rise to contrasting results. While 8-chloro substituted pyrimidines have null or scarce 
activity when R = H (compound 2g) or R = OCH3 (compound 2h), the 4'-chloro analogue 
2i (R = Cl) is surprisingly the most effective to inhibit HUVEC cells growth of the whole 
series. The less performing was sub-series 3, actually benzilamino-pyrimidines 3a-i that 
displayed comparable and low cytotoxic potencies, independently of the presence of a 
hydrogen, a methoxy group or a chlorine in the 8 (X) and/or 4' (R) positions. In this latter 
series of analogues the increase in the distance between the phenyl ring and the amine 
linker through a methylene spacer seems accountable for the almost disappearance of 
cytotoxicity, and the dependence of the cellular effects on the other groups appears 
responsible only for slightly different biological activities. 
Overall, the above results confirm the important role played by the NH spacer group, given 
that only the 2-anilino pyrimidines 2a-i showed both significant KDR inhibition potency 
and HUVECs antiproliferative activity, likely correlating the VEGF/VEGFR signal system 
with their cellular activity. 
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2.2.3. Inhibition of VEGFR-2 phosphorylation in endothelial cells. 
The efficacy observed on HUVEC cells was further investigated by evaluating the 
ability of the most cytotoxic derivatives, namely 2b, 2e, and 2i, to inhibit the 
phosphorylation of the target receptor on whole cells [34]. After exposure to 2b (fig. 1A), 
2e (fig. 1B), and 2i (fig. 1C) at different concentrations, the amount of the phosphorylated 
form of VEGFR-2 in HUVEC cell lysates was significantly reduced at the highest 
concentration (2.5 µM).  
 
Figure 1. Inhibition of VEGFR-2 phosphorylation by 2b (A), 2e (B) and 2i (C) 
compounds in HUVEC cells after 72 h of treatment. pVEGFR-2 concentrations were 
measured by ELISA kits and they were normalized to total VEGFR-2 protein 
concentration. Columns and bars, mean values ± SD, respectively. *P<0.05 vs. vehicle-
treated controls. 
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In particular, in samples treated with 2b and 2i the amount of phosphorylated form of 
VEGFR-2 significantly decreased in a concentration-dependent manner, starting at the 
experimental GI50 of cell proliferation (figs. 1B and C). 
 
2.2.4. Ex vivo anti-angiogenic activity evaluation 
Angiogenesis assays are essential for the identification of potential pro-angiogenic 
agents as well as for the screening of pharmacological inhibitors. Among them, the ex vivo 
“rat aortic ring" assay, initially developed by Nicosia and Ottinetti [35], bridges the gap 
between in vivo and in vitro models. Actually, by using intact vascular explants, the 
environment in which angiogenesis takes place results more accurately reproduced than 
that with isolated endothelial cells [36]. Considering that the organization of endothelial 
cells in capillary-like structures is a process that better occurs in a 3-dimensional 
extracellular matrix, the culture of rat aortic explants in a matrix of this type results one of 
the most effective ways for generating new capillaries in vitro. 
In order to assess their capacity to inhibit microvessel sprouting in an angiogenic process, 
the selected 2-anilino substituted derivatives 2b and 2i have been tested in the ex-vivo “rat 
aortic ring assay”. Aortic explants were incubated with compounds 2b and 2i, at different 
concentrations (100 nM, 1 µM, 5 µM and 10 µM) and the activity was compared with that 
exerted by the reference drug  Semaxanib, at the same concentrations, (figs. 2 and 3). 
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Figure 2. Representative images of the inhibition of microvessel sprouting by compounds 
2b, and 2i at [100 nM], [1 µM], [5 µM], [10 M], compared with DMSO and Semaxanib 
at the same concentrations. Images were visualized using a Nikon fluorescence microscope 
Eclipse E800 equipped with Nikon camera, with the 4x objective, after fluorescence cell 
staining at day 7th of the experiment. All experiments have been conducted in duplicate and 
at least on two different animals. 
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Figure 3. Comparison of the angiogenic growth (Y = Length, µms) of rat aortic explants 
cultured with compounds 2b and 2i at different concentrations (X = 100nM ;1μM; 5μM; 
10μM). DMSO is used as control and Semaxanib as reference compound. Data were 
calculated at day 7th of the experiment and represent the mean of n = 2-4 
 
Interestingly, both selected compounds inhibit the angiogenic sprouting in aortic ring 
assay, and the use of different concentrations allowed us to identify the range in which the 
inhibition took place. In particular, the benzothiopyrano derivatives 2b and 2i, seemed to 
inhibit the process at concentrations ranging from 1 to 5µM, showing a profile similar to 
that of the reference standard Semaxanib.  
 
 
 
2.2.5. Evaluation on HeLa, A-431 and MSTO-211H tumour cell lines 
The high structural similarity of kinase ATP binding pocket has made the development 
of selective inhibitors extremely challenging. Actually, most of the developed angio-kinase 
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inhibitors also hit a broad range of additional protein kinases; however, a significant 
capacity to affect simultaneously different mitogenic patways, is often associated with 
serious side effects and toxicities [37, 38]. In this regard, we studied the cell proliferation 
profile of the benzothiopyrano collection of compounds 1, 2 and 3 against a panel of 
human tumour cell lines expressing different kinases: HeLa (cervix adenocarcinoma), A-
431 (epidermoid carcinoma) and MSTO-211H (biphasic mesothelioma). As reported in 
Table 2, the cell growth evaluation once again revealed a crucial role for the length of the 
side chain and the presence of the NH group, as evident cytotoxic effects have been 
observed for the most part of 2-anilino substituted derivatives 2, showing GI50 values in the 
micromolar range. In addition, a notable effect might also be attributable to the p-methoxy 
substituent on the pendant phenyl ring (R = OCH3), being 2b and 2e the most effective 
derivatives. The p-chlorine (R = Cl) substitution seems to be detrimental, with the 
exception of 2i in which, accordingly with the above discussed results, a good activity was 
present by introducing a chlorine atom on the 8-position (X = Cl). 
 
Table 2. Human Tumour Cell Growth Inhibition of Derivatives 1a-i, 2a-i and 3a-i. 
 
  GI50a (M)  
Compd. HeLa A-431 MSTO-211H 
1a >20 >20 >20 
1b >20 >20 >20 
1c >20 >20 >20 
1d >20 6.51.2 11.91.1 
1e >20 >20 >20 
1f >20 >20 >20 
1g >20 >20 >20 
1h >20 >20 >20 
1i >20 >20 >20 
2a 10.22.1 >20 11.71.3 
2b 0.70.5 0.960.25 1.080.04 
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2c 15.62.2 >20 11.51.5 
2d 20.1 >20 15.01.6 
2e 0.830.14 0.960.2 1.080.2 
2f >20 >20 >20 
2g >20 >20 >20 
2h 2.10.2 5.80.4 20 
2i 1.50.4 2.20.4 1.60.3 
3a >20 >20 >20 
3b >20 >20 >20 
3c >20 >20 >20 
3d >20 >20 >20 
3e >20 >20 >20 
3f >20 >20 >20 
3g >20 >20 >20 
3h >20 >20 >20 
3i >20 >20 >20 
 
a GI50 values represent the concentration (M) of compound able to produce 50% cell 
death with respect to the control culture. 
 
Between the others subseries, 1a-i and 3a-i, only derivative 1d shows a detectable 
antiproliferative effect, which appears more significant in A-431 cells. 
 
2.2.6. EGFR inhibition assay 
Important evidences point out numerous cross-talks between activated epidermal 
growth factor receptor (EGFR) largely expressed on A-431 cells and VEGFR [34, 39], 
moreover a dose-dependent decrease in VEGF expression in EGFR-responsive A-431 cells 
was indicated for different classes of EGFR targeting agents [40]. Accordingly, the 
capability of compounds 1d and 2a-i to bind EGFR was assayed. The inhibitory effect of 
the test compounds was routinely estimated at 100 M, following a previously reported 
protocol [41, 42]. Compounds 2a-f displayed null or low percentage values of kinase 
inhibition, while compounds 1d and 2g-i showed a certain capacity to reduce the kinase 
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activity. These latter compounds, whose percentage values of inhibition were higher than 
80%, have been tested at additional concentrations calculating the IC50 values, exploiting 
gefitinib as reference standard (Table 3). Significantly, the shortened derivative 1d 
displayed an IC50 value of 4.72 M, in accordance with its antiproliferative activity on A-
431 cell line. 
 
Table 3. EGFR Inhibition Data of Derivatives 1d and 2a-2i. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPercentage of kinase inhibition obtained at 100 M test compound. 
b IC50 values represent the concentration that induces the 50% reduction in enzyme activity. 
c not active, d not determined 
 
 
2.2.7. Kinases inhibition assays 
The high inhibitory effect of 2b and 2i on VEGFR phosphorylation and of 1d on 
EGFR kinase activity, prompt us to deepen their kinase selectivity profile. In particular, 
Compd. EGFR 
%a 
EGFR 
IC50b (M) 
1d 100 4.72 
2a 50 n.d.d 
2b < 50 n.d.d 
2c < 50 n.d.d 
2d 57 n.d.d 
2e < 50 n.d.d 
2f n. a.c n.d.d 
2g 100 21.18 
2h 93 21.56 
2i 81 45.70 
Gefitinib   0.022  
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their effect has been assessed against a set of 10 human kinases (Akt1/PKB, AurA/Aur2 
kinase, CDC2/CDK1, ERK1, FAK, MEK1/MAP2K1, PDGFR kinase, RAF-1 kinase, 
ROCK1, Src kinase), which are reported to be mainly involved in cell proliferation. No 
inhibitory activity was detected for 1d and 2i, when assayed at 10 μM concentrations 
(Figs. 4a and 4c), thus excluding any involvement of the tested kinases in the effects of 
these derivatives on cell viability. Only compound 2b might appear a multi-target inhibitor 
of tyrosine kinases, inhibiting besides VEGFR-2, also Aurora kinase and CDC2/CDK1 at 
significant extent (Fig. 4b). 
 
 
 
Figure 4a. Kinases Inhibitory Activities of compound 1d. 
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Figure 4b. Kinases Inhibitory Activities of compound 2b. 
 
 
Figure 4c. Kinases Inhibitory Activities of compound 2i. 
 
2.3. Molecular Modelling 
 
To better understand the reasons behind the VEGFR-2 inhibitory activity of the 
compounds described above, molecular docking studies were performed on compound 2b. 
It displays the highest, although not selective, VEGFR-2 kinase activity inhibitory property 
(IC50 2.7 µM), high antiproliferative activity on both HUVECs and tumour cell lines 
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(HeLa, A-431 and MSTO-211H), as well as evident anti-angiogenic properties in the ex 
vivo rat aortic assay.  
These calculations were attained using the AD4 software [43, 44]. This choice was dictated 
by results of a recent work in which this program was demonstrated to be the best in 
reproducing the experimental (X-Ray) binding pose for different kinases in cross-docking 
experiments among 17 different docking procedures [45]. To date, more than 30 crystal 
structures of VEGFR-2 in complex with several inhibitors have been reported. In this 
inspection, we decided to consider only the structures having a resolution below 2Å 
(1YWN [46], 2P2H [47], 2XIR, 3BE2 [48], 3EWH [49], 3VHE [50], 3VNT [51], 4AG8 
[52], 4ASE [53], 3VO3 [54]) in which 1YWN displayed the so-called A-loop (activation 
loop) in its open conformation while all the others had the same protein region in its closed 
form. Among these, the structure 4AG8 was used, as it demonstrated to be the best 
performing one in AD4 cross-docking experiments. In particular, employing this structure, 
AD4 was able to reproduce the X-ray conformation of all the analysed co-crystal ligand 
with an average root-mean squared deviation (rmsd) of 0.89 Å (see Table 4). 
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Table 4. Rmsd values resulting from cross-docking experiments on the 9 considered 
VEGFR-2 structures. 
 
  Ligands  
  1YWN 2P2H 2XIR 3BE2 3EWH 3VHE 3VNT 4AG8 4ASE 
Average 
rmsd 
R
ec
ep
to
rs
 
1YWN 0.66 9.55 6.76 0.83 1.16 5.60 6.72 10.66 11.32 5.92 
2P2H 1.57 5.19 10.37 1.48 1.44 1.40 8.72 11.98 8.43 5.62 
2XIR 12.39 11.99 1.90 11.82 2.33 1.72 2.01 1.96 2.19 5.37 
3BE2 3.11 7.97 2.98 1.26 1.03 3.03 6.86 12.83 3.03 4.68 
3EWH 1.17 9.12 2.79 0.90 1.82 2.79 3.19 2.83 2.91 3.06 
3VHE 1.45 11.56 0.85 3.64 0.94 0.83 0.64 0.94 0.79 2.41 
3VNT 10.38 10.75 0.66 1.54 0.95 1.16 0.43 0.46 0.58 2.99 
4AG8 1.17 1.49 0.58 1.92 0.97 0.69 0.58 0.42 0.69 0.95 
4ASE 0.89 10.74 0.54 3.06 0.96 0.60 0.39 0.59 0.27 2.01 
 
 
Interestingly, the 200 independent docking runs of 2b within the VEGFR-2 kinase active 
site converged toward a single cluster solution (i.e. binding conformation differing by less 
than 1.5 Å) for which a binding free energy (ΔGAD4) of -7.62 kcal/mol was predicted (Fig. 
5).  
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Figure 5. Binding mode of compound 2b, within the VEGFR-2 active site. The ligand is 
represented as green sticks while the protein as orange sticks and ribbons. H-bonds are 
depicted as dashed yellow lines. The picture was rendered with the UCSF Chimera 
software. [55]  
 
In this conformation, the benzothiopyranopyrimidine scaffold is inserted in the enzyme 
active site with its nitrogen in position 3 and the adjacent exocyclic NH in position 2 
establishing a double H-bond with the backbone NH and CO of Cys919 in the enzyme 
hinge region, respectively. These interactions explain why 2b and its closely related 
congeners are effective VEGFR-2 inhibitors and why the 2-aryl analogues (1a-i), by 
lacking the double H-bond interaction generally display lower inhibition against the 
enzyme (Table 1). Moreover, the lipophilic benzothiopyranopyrimidine ring is fitting in 
the hydrophobic ATP cleft where favorable contacts are established with Leu1035, 
Val899, Val916 (gate-keeper residue), Val848, and Leu840. The limited extension of this 
cleft would not allow to easily host bulky substituents in position 8 of the chromophore 
without a subsequent relocation of the ligand. Indeed, this relocation would result in the 
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loss of the double H-bond interaction with the enzyme’s hinge region residues, thus 
explaining the lower inhibition potencies of compounds 2d-2h. On the other hand, the 
presence of the positively charged K868, within the same cleft, should negatively affect the 
ligand/enzyme recognition suggesting that modifications of the 
benzothiopyranopyrimidine scaffold, aimed at minimizing these unfavourable contacts, 
should enhance the inhibitory potencies against the enzyme. We are now testing this 
hypothesis and results will be reported in due of course. In the binding site, Phe1047 is 
placed between the benzothiopyrane aromatic ring and the aniline moiety in position 2 of 
the tricyclic system establishing with them charge-transfer interactions. In this respect, it 
could be speculated that the double substitution in position 8 (X) and 4' (R) with the 
electron withdrawing chlorine atom would enhance the strength of the aforementioned 
interaction thereby explaining why 2i is still so efficient as VEGFR-2 kinase inhibitor. 
The aniline substituent is partially solvent exposed and this should explain why its 
substitution with the longer 2-benzylamino group would result in weaker VEGFR-2 
inhibitors (3a-i). As depicted in Figure 5, the p-methoxy substituent of 2b is pointing 
towards Asn923 residue and in principle additional H-bond interactions could be 
established through the rearrangement of this residue. 
 
3. Conclusions 
 
Activation of the “angiogenic switch” is considered one of the most critical factors for 
tumour growth and progression, and numerous small molecule inhibitors of the VEGF-
VEGFR pathways have been proven to be an attractive approach for anticancer drug 
discovery. 
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In this work, we developed novel antiangiogenic agents based on the benzothiopyrano[4,3-
d]pyrimidine scaffold, characterized by a pendant aryl moiety. In particular, the synthesis 
of new benzothiopyrano[4,3-d]pyrimidines carrying phenyl (compounds 1a-i), phenyl-
amino (compounds 2a-i) and benzyl-amino (compounds 3a-i) side groups in the 2-position 
of the heterocyclic system is described. Of these derivatives, compounds 2a-i emerged as 
the most interesting, revealing that the presence of the anilino side moiety is required to 
obtain a significant effect against the target proteins. 
Compounds 2a-i displayed a promising inhibitory profile on both human kinase receptor 
KDR and endothelial HUVEC cells, with values in the low micromolar range. The kinase 
inhibitory activities of the best performing compounds 2b and 2i was further investigated 
by measuring the formation of newly phosphorylated substrates via a cell-based phospho-
VEGFR-2 inhibition assay. Moreover, their capacity to inhibit the generation of new 
capillaries was confirmed by means of the ex-vivo “rat aortic ring assay”.  
To determine the compounds’ selectivity profile, we evaluated the cytotoxic effects of 1a-i, 
2a-i and 3a-i against three human tumour cell lines. As a general trend, only few 
compounds, belonging to the subseries 2, retained cytotoxic activity, albeit with about a 2-
fold increase in GI50 values with respect to HUVECs. Hence, in order to investigate the 
involvement of other structurally related kinases in the cellular activity, we assayed the 
capacity of compounds 2b and 2i to interfere with a panel of eleven additional human 
kinases, (EGFR, Akt1/PKB, AurA/Aur2, CDC2/CDK1, ERK1, FAK, MEK1/MAP2K1, 
PDGFR, RAF-1, ROCK1 and Src kinase).  By this study, the most selective derivative 
seems to be 2i, conversely, the best performing compound 2b exhibited a certain activity 
also against Aurora kinase and CDC2/CDK1, probably due to the high structural 
similarities shared by the VEGFR-2 ATP binding pocket with that of other kinases. 
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Molecular docking calculations allowed understanding the interaction pattern established 
by the compounds and the KDR domain of VEGFR-2. The model, exploited for compound 
2b, showed that the benzothiopyranopyrimidine scaffold could interact with the enzyme 
active site, with its nitrogen in position 3 and the adjacent aniline NH in position 2 
establishing a double H-bond with the backbone NH and CO of Cys919, in the enzyme 
hinge region, respectively; thus corroborating the crucial role of the 2-anilino side moiety.  
In conclusion, the ability to exert evident inhibitory effects against VEGFR-2, both in vitro 
and in endothelial cells, together with noteworthy cytotoxicity on HUVECs and ex vivo 
antiangiogenic activity, render the new 2-anilino substituted heteropolycyclic moiety an 
interesting structure inside the field of VEGFR-2-targeted antitumor agents. Thus, further 
structural optimization of this promising system is in progress in our laboratories, with the 
purpose of obtaining new antiangiogenic active candidates. 
 
4. Experimental 
 
4.1. Chemistry 
 
4.1.1. General 
The uncorrected melting points were determined using a Reichert Köfler hot-stage 
apparatus. NMR spectra were obtained on a Bruker AVANCE 400 (1H, 400 MHz, 13C, 100 
MHz) in DMSO-d6 (internal standard tetramethylsilane). The coupling constants are given 
in Hertz. Elemental analyses were performed by our Analytical Laboratory and were 
within ± 0.4%. Magnesium sulphate was used as the drying agent. Evaporations were made 
in vacuo (rotating evaporator). Analytical TLC have been carried out on Merck 0.2 mm 
precoated silica gel aluminium sheets (60 F-254). Silica gel 60 (230-400 mesh) was used 
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for column chromatography. Combustion analyses on target compounds were performed 
by our Analytical Laboratory in Pisa. All compounds showed ≥ 95% purity. Reagents, 
starting materials, and solvents were purchased from commercial suppliers and used as 
received. According to the methods described previously the following substrates were 
obtained: 3-Dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-4(4H)-one 4a, 
[22] 7-Methoxy-3-dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-4(4H)-
one 4b [24], 7-Chloro-3-dimethylaminomethylen-2,3-dihydrobenzo[3',2':5,6]thiopyran-
4(4H)-one 4c [20], 4-Substituted-benzamidines hydrochlorides 5b-c [27,28] and 4-
Substituted-benzylguanidines sulphate 6a-c [29-31]. 
 
4.1.2. General synthetic procedures for 8-substituted-2-amino-5H-benzothiopyrano[4,3-
d]pyrimidines 7a-c  
Guanidine hydrochloride (0.160 g, 1.70 mmol) was added, at room temperature, under 
a nitrogen atmosphere, to a stirred solution of sodium ethoxide (0.059 g, 2.55 mmol of 
sodium in 8 mL of anhydrous ethanol). The resulting suspension was stirred at room 
temperature for 15 minutes, then the opportune dimethylaminomethylene derivative 4a-c 
(0.85 mmol) was added and the reaction mixture was refluxed for 6 h. After cooling, the 
resulting suspension was concentrated under reduced pressure and the residue obtained 
was washed with water and collected to give crude pyrimidines 7a-c, which were purified 
by recrystallization from ethanol.  
Compound 7a was already described even if it was obtained with a different synthetic 
procedure [56]. Compound 7b was already described by us [20]. 
 
4.1.2.1. 8-Chloro-2-amino-5H-benzothiopyrano[4,3-d]pyrimidine (7c). 75% yield. m. p. 
180-182 °C; 1H-NMR (dimethyl-d6 sulfoxide):  3.95 (s, 2H, CH2S); 6.71 (s, 2H, NH2 
exch.) 7.35-7.41 (dd, 1H, 9-ArH J9-10 = 8.2Hz J9-7 = 2.2 Hz); 7.51 (d, 1H, 7-ArH J7-9 = 2.0 
Hz); 8.17 (d, 1H, 10-H J10-9 = 8.0 Hz); 8.24 (s, 1H, 4-ArH). Anal. Calcd. for C11H8ClN3S: 
C, 52.90; H, 3.21; N, 16.83; Found: C, 52.75; H, 3.24; N, 16.85. 
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4.1.3. General synthetic procedures for 8-Substituted-2-(p-substituted-phenyl)-5H-
benzothiopyrane[4,3-d]pyrimidines 1a-i 
The appropriate benzamidine hydrochloride 5a-c (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide (0.059 g, 
2.55 mmoles of sodium in 8 mL of anhydrous ethanol). The resulting suspension was 
stirred at room temperature for 15 minutes, then the opportune dimethylaminomethylene 
derivative 4a-c (0.187 g, 0.85 mmoles) was added and the reaction mixture was refluxed 
for 6 hours. After cooling, the suspension was concentrated under reduced pressure. The 
residue obtained was washed with water and collected, to give crude pyrimidines 1a-i, 
which were purified by recrystallization from ethanol. 
Compound 1a was already described [57] even if it was obtained by a different synthetic 
procedure. Compound 1d was already described by us [20]. 
 
4.1.3.1. 2-(p-methoxy-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1b). Yield: 30%; M. 
p. 108-110 °C; 1H NMR (400 Hz, DMSOd6):  3.85 (S, 3H, 4'-OCH3); 4.16 (s, 2H, CH2S); 
7.10 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 7.43-7.49 (m, 3H, 7-, 8-, 9-ArH); 8.45 (dd, 2H, 3',5'-
ArH, J = 8.6 Hz); 8.52-8.55 (dd, 1H, 10-ArH); 8.81 (s, 1H, 4-ArH). 13C NMR (100 Hz, 
DMSOd6):  26.00, 55.54, 113.52, 114.02, 121.37, 126.01, 128.53, 130.57, 135.61, 
136.13, 138.61, 156.41, 161.52. Elemental analysis for C18H14N2OS. Calculated: % C, 
70.56; % H, 4.61; % N, 9.14; found % C, 70.17; % H, 4.82; % N, 9.36 
 
4.1.3.2. 2-(p-chloro-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1c). Yield: 24%; M. p. 
114-116 °C; 1H NMR (400 Hz, DMSOd6):  4.20 (s, 2H, CH2S); 7.42-7.51 (m, 3H, 7-, 8-, 
9-ArH); 7.63 (d, 2H, 2',6'-ArH); 8.49-8.56 (m, 3H, 3',5'-, 10-ArH); 8.89 (s, 1H, 4-ArH). 
13C NMR (100 Hz, DMSOd6):  26.04, 119.32, 126.14, 127.72, 128.92, 129.34, 132.51, 
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134.36, 137.04, 156.81, 161.54.  Elemental analysis for C17H11ClN2S. Calculated: % C, 
65.70; % H, 3.57; % N, 9.01; found % C, 66.02; % H, 3.44; % N, 9.23 
 
4.1.3.3. 8-Methoxy-2-(p-methoxy-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1e). 
Yield: 40%; M. p. 186-188 °C; 1H NMR (400 Hz, DMSOd6):  3.85 (S, 6H, 8-OCH3, 4'-
OCH3); 4.14 (s, 2H, CH2S); 6.96-7.02 (m, 2H, 7-, 9-ArH); 7.09 (d, 2H, 2',6'-ArH, J = 8.6 
Hz); 8.41-8.49 (m, 3H, 3',5'-, 10-ArH); 8.73 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 
 26.25, 54.89, 55.52, 111.32, 111.45, 114.86, 124.18, 126.27, 127.31, 130.36, 138.04, 
158.82, 160.85, 162.18. Elemental analysis for C19H16N2O2S. Calculated: % C, 67.84; % 
H, 4.79; % N, 8.33; found % C, 67.58; % H, 4.59; % N, 8.21 
 
4.1.3.4. 8-Methoxy-2-(p-chloro-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1f). Yield: 
35%; M. p. 142-144 °C; 1H NMR (400 Hz, DMSOd6):  3.86 (S, 3H, 8-OCH3); 4.17 (s, 
2H, CH2S); 6.96-7.03 (m, 2H, 7-, 9-ArH); 7.61 (d, 2H, 2',6'-ArH); 8.46-8.51 (m, 3H, 3',5'-, 
10-ArH); 8.79 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.24, 55.60, 112.01, 
113.33, 121.31, 124.37, 128.70, 129.03, 129.36, 135.53, 136.04, 138.45, 155.40, 157.41, 
161.12, 161.70. Elemental analysis for C18H13ClN2OS. Calculated: % C, 63.43; % H, 3.84; 
% N, 8.22; found % C, 63.25; % H, 3.63; % N, 7.99 
 
4.1.3.5. 8-Chloro-2-phenyl-5H-benzothiopyrane[4,3-d]pyrimidine (1g). Yield: 14%; M. p. 
117-119 °C; 1H NMR (400 Hz, DMSOd6):  4.22 (s, 2H, CH2S); 7.46-7.51 (dd, 1H, 9-ArH 
J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.54-7.57 (m, 3H, 2'-, 4'-, 6'-ArH); 7.62 (d, 1H, 7-ArH, J = 
2.0 Hz); 8.47-8.57 (m, 3H, 3'-, 5'-, 10-ArH); 8.88 (s, 1H, 4-ArH). 13C NMR (100 Hz, 
DMSOd6):  26.22, 117.18, 125.72, 126.18, 127.54, 128.58, 129.21, 131.19, 135.10, 
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158.78, 161.19. Elemental analysis for C17H11ClN2S. Calculated: % C, 65.70; % H, 3.57; 
% N, 9.01; found % C, 65.59; % H, 3.67; % N, 8.89 
 
4.1.3.6. 8-Chloro-2-(p-methoxy-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1h). 
Yield: 13%; M. p. 142-144 °C; 1H NMR (400 Hz, DMSOd6):  3.86 (S, 3H, 8-OCH3); 4.21 
(s, 2H, CH2S); 7.11 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 7.47-7.52 (dd, 1H, 9-ArH, J9-10 = 8.6 
Hz, J9-7 = 2.2 Hz); 7.63 (d, 1H, 7-ArH, J = 2.2 Hz); 8.45 (d, 2H, 3',5'-ArH, J = 8.8 Hz); 
8.53 (d, 1H, 10-ArH, J = 8.4 Hz); 8.90 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6):  
26.23, 55.58, 114.83, 117.21, 125.63, 126.15, 128.56, 130.31, 133.46, 138.47, 158.81, 
160.64, 162.21. Elemental analysis for C18H13ClN2OS. Calculated: % C, 63.43; % H, 3.84; 
% N, 8.22; found % C, 63.33; % H, 3.64; % N, 7.87 
 
4.1.3.7. 8-Chloro-2-(p-chloro-phenyl)-5H-benzothiopyrane[4,3-d]pyrimidine (1i). Yield: 
15%; M. p. 165-167 °C; 1H NMR (400 Hz, DMSOd6):  4.24 (s, 2H, CH2S); 7.46-7.52 (dd, 
1H, 9-ArH J9-10 = 8.4 Hz, J9-7 = 2.0 Hz); 7.61-7.65 (m, 3H, 2',6'-, 7-ArH); 8.49 (m, 3H, 
3',5'-, 10-ArH); 8.90 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.23, 122.31, 
126.54, 127.15, 128.77, 128.90, 129.42, 130.46, 135.74, 135.75, 136.26, 138.78, 156.14, 
156.64, 161.34. Elemental analysis for C17H10Cl2N2S. Calculated: % C, 59.14; % H, 2.92; 
% N, 8.11; found % C, 59.36; % H, 3.12; % N, 7.94 
 
4.1.4. General synthetic procedures for 8-Substituted-2-(p-substituted-anilino)-5H-
benzothiopyrane[4,3-d]pyrimidines 2a-i 
The opportune 8-substituted-2-amino-5H-benzothiopyrane[4,3-d]pyrimidine 7a-c (0.417 
mmoles) was added, at room temperature, under nitrogen atmosphere, to 0.079 g of CuI 
(0.417 mmoles) and 0.115 g of anhydrous K2CO3 (0.833 mmoles). Then, the appropriate 
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aryl iodide (0.694 mmoles) and 0.04 mL of DMEDA (0.417 mmoles) and 2.5 mL of 
dioxane were added. The reaction mixture was heated at 100 °C and allowed to stir for 24 
hours. After cooling, the mixture was supplemented with 2.5 mL of concentrated NH3 
aqueous solution and 10-15 mL of a saturated solution of NaCl. The reaction mixture was 
extracted with ethylacetate and the organic layers obtained were evaporated under reduced 
pressure giving a residue. This latter was purified by flash chromatography using 
petroleum ether 60-80 °C/ethyl acetate 70:30 as the eluting system, to yield compounds 
2a-i. 
Compound 2a has been already described [41], even it was obtained by a different 
synthetic pathway. 
 
4.1.4.1. 2-anilino-5H-benzothiopyrane[4,3-d]pyrimidine (2a). Yield: 22 %; M. p. 161-162 
°C; 1H NMR (400 Hz, DMSOd6):  4.02 (s, 2H, CH2S); 6.97 (t, 1H, 4'-ArH); 7.31 (t, 2H, 
8,9-ArH); 7.38-7.43 (m, 3H, 7, 3',5'-ArH); 7.81 (d, 2H, 2',6'-ArH J = 7,6 Hz); 8.29 (d, 1H, 
10-ArH J = 7,2 Hz ); 8.46 (s, 1H, 4-ArH); 9.68(s, 1H, NH exch.). 13C NMR (100 Hz, 
DMSOd6): 25.92, 115.11, 118.67, 121.27, 126.22, 127.02, 127.90, 128.50, 131.14, 
132.09, 136.52, 140.55, 156.39, 157.73, 159.36. Elemental analysis for C17H13N3S. 
Calculated: % C, 70.08; % H, 4.50; % N, 14.42; found % C, 69.93; % H, 4.56; % N, 14.36 
 
4.1.4.2. 2-(p-methoxy-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2b). Yield: 16%; M. 
p. 164-165 °C; 1H NMR (400 Hz, DMSOd6):  3.74 (S, 3H, 8-OCH3); 4.00 (s, 2H, CH2S); 
6.91 (d, 2H, 2',6'-ArH J = 9,0 Hz); 7.35-7.44 (m, 3H, 7-, 8-, 9-ArH); 7.69 (d, 2H, 3',5'-ArH 
J = 9.0 Hz); 8.26-8.29 (dd, 1H, 10-ArH); 8.42 (s, 1H, 4-ArH); 9.47 (s, 1H, NH exch.). 13C 
NMR (100 Hz, DMSOd6):  25.91. 55.57, 115,17, 118.76, 119.14, 121.76, 125.63, 127.81, 
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128.64, 131.24, 132.56, 137.03, 159.91, 163.24. Elemental analysis for C18H15N3OS. 
Calculated: % C, 67.27; % H, 4.70; % N, 13.07; found % C, 67.43; % H, 4.56; % N, 12.96 
 
4.1.4.3. 2-(p-chloro-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2c).  Yield: 23%; M. 
p. 226-228 °C; 1H NMR (400 Hz, DMSOd6):  4.03 (s, 2H, CH2S); 7.34-7.45 (m, 5H, 3'-, 
5'-, 7-, 8-, 9-ArH); 7.85 (d, 2H, 2',6'-ArH J = 9.0 Hz); 8.29 (d, 1H, 10-ArH); 8.49 (s, 1H, 4-
ArH); 9.86 (s, 1H, NH exch.). 13C NMR (100 Hz, DMSOd6):  25.93, 118.61, 119.27, 
122.34, 125.71, 127.72, 128.61, 129.67, 132.51, 137.04, 159.91, 163.42. Elemental 
analysis for C17H12ClN3S. Calculated: %C, 62.67; % H, 3.71; % N, 12.90; found % C, 
62.84; % H, 3.58; % N, 13.11 
 
4.1.4.4. 8-Methoxy-2-anilino-5H-benzothiopyrane[4,3-d]pyrimidine (2d). Yield: 13%; M. 
p. 174-176 °C; 1H NMR (400 Hz, DMSOd6):  3.83 (S, 3H, 8-OCH3); 4.01 (s, 2H, CH2S); 
6.91-6.99 (m, 3H, 7-, 9-, 4'-ArH); 7.30 (t, 2H, 3',5'-ArH); 7.81 (d, 2H, 2',6'-ArH); 8.24 (d, 
1H, 10-ArH); 8.40 (s, 1H, 4-ArH); 9.61 (s, 1H, NH exch.). 13C NMR (100 Hz, DMSOd6): 
 26.19, 111.27, 117.83, 118.61, 122.48, 124.13, 129.52, 159.91, 160.82, 164.82, 164.38, 
167.21. Elemental analysis for C18H15N3OS. Calculated: %C, 67.27; % H, 4.70; % N, 
13.07; found % C, 66.96; % H, 4.87; % N, 13.24 
 
4.1.4.5. 8-Methoxy-2-(p-methoxy-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2e). 
Yield: 12%; M. p. 195-197 °C; 1H NMR (400 Hz, DMSOd6):  3.74 (S, 3H, 4'-OCH3); 
3.83 (S, 3H, 8-OCH3); 4.00 (s, 2H, CH2S); 6.88-6.98 (m, 4H, 2',6'-, 7-, 9-ArH); 7.69 (d, 
2H, 3',5'-ArH, J = 9.0 Hz); 8.22 (d, 1H, 10-ArH, J = 9.0 Hz); 8.35 (s, 1H, 4-ArH); 9.40 (s, 
1H, NH exch.). 13C NMR (100 Hz, DMSOd6): 26.21, 54.92, 55.56, 111.34, 112.05, 
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115.17, 118.62, 121.73, 124.16, 131.22, 138.09, 153.36, 159.97, 160.82, 164.82. Elemental 
analysis for C19H17N3O2S. Calculated: % C, 64.94; % H, 4.88; % N, 11.96; found % C, 
65.22; % H, 5.09; % N, 12.11 
 
4.1.4.6. 8-Methoxy-2-(p-chloro-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2f). Yield: 
35%; M. p. 214-216 °C; 1H NMR (400 Hz, DMSOd6):  3.83 (S, 3H, OCH3); 4.02 (s, 2H, 
CH2S); 6.94-6.99 (dd, 2H, 7-, 9-ArH); 7.35 (d, 2H, 3',5'-ArH, J = 9.0 Hz); 7.84 (d, 2H, 
2',6'-ArH, J = 8.8 Hz); 8.23 (d, 1H, 10-ArH, J = 8.2 Hz); 8.42 (s, 1H, 4-ArH); 9.79 (s, 1H, 
NH exch.). 13C NMR (100 Hz, DMSOd6): 26.13, 55.54, 112.16, 112.98, 114.31, 119.99, 
124.52, 124.67, 128.30, 128.76, 138.48, 139.66, 155.87, 157.82, 159.01, 161.32. Elemental 
analysis for C18H14ClN3OS. Calculated: % C, 60.76; % H, 3.97; % N, 11.81; found % C, 
60.52; % H, 3.78; % N, 11.73 
 
4.1.4.7. 8-Chloro-2-anilino-5H-benzothiopyrane[4,3-d]pyrimidine (2g). Yield: 70%; M. p. 
222-224 °C; 1H NMR (400 Hz, DMSOd6):  4.06 (s, 2H, CH2S); 6.97 (t, 1H, 4'-ArH); 7.36 
(t, 2H, 3',5'-ArH);7.44-7.49(dd, 1H, 9-ArH J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.57 (d, 1H, 7-
ArH); 7.80 (d, 2H, 2',6'-ArH); 8.27 (d, 1H, 10-ArH J = 8.6 Hz); 8.49 (s, 1H, 4-ArH); 9.73 
(s, 1H, NH exch.).  13C NMR (100 Hz, DMSOd6): 25.90, 114.71, 118.75, 121.37, 127.13, 
128.49, 128.53, 130.90, 135.69, 138.85, 140.43, 156.61, 156.91, 159.36. Elemental 
analysis for C17H12ClN3S. Calculated: % C, 62.67; % H, 3.71; % N, 12.90; found % C, 
62.41; % H, 3.44; % N, 13.11 
 
4.1.4.8. 8-Chloro-2-(p-methoxy-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2h). 
Yield: 10%; M. p. 205-207 °C; 1H NMR (400 Hz, DMSOd6):  3.74 (S, 3H, 4'-OCH3); 
4.05 (s, 2H, CH2S); 6.91 (d, 2H, 3',5'-ArH, J = 9.0 Hz); 7.43-7.48 (dd, 1H, 9-ArH); 7.56 (d, 
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1H, 7-ArH); 7.67 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 8.25 (d, 1H, 10-ArH); 8.44 (s, 1H, 4-
ArH); 9.52 (s, 1H, NH exch.). 13C NMR (100 Hz, DMSOd6): 
35.58, 
138.80, 154.21, 156.59, 156.83, 159.53 Elemental analysis for C18H14ClN3OS. Calculated: 
% C, 60.76; % H, 3.97; % N, 11.81; found %C, 60.96; %H, 3.66; % N, 12.17 
 
4.1.4.9. 8-Chloro-2-(p-chloro-anilino)-5H-benzothiopyrane[4,3-d]pyrimidine (2i) Yield: 
12%; M. p. 170-172 °C; 1H NMR (400 Hz, DMSOd6):  4.06 (s, 2H, CH2S); 7.36 (d, 2H, 
3',5'-ArH, J = 8.8 Hz); 7.41-7.47 (dd, 1H, 9-ArH J9-10 = 8.6 Hz, J9-7 = 2.2 Hz); 7.57 (d, 1H, 
7-ArH, J = 2.2 Hz); 7.83 (d, 2H, 2',6'-ArH, J = 9.0 Hz); 8.26 (d, 1H, 10-ArH, J = 8.6 Hz); 
8.50 (s, 1H, 4-ArH); 9.89 (s, 1H, NH exch.). 13C NMR (100 Hz, DMSOd6): 25.89, 
115.12, 120.15, 124.78, 126.35, 127.16, 128.36, 128.63, 130.79, 131.54, 135.78, 138.92, 
139.45, 156.63, 159.11. Elemental analysis for C17H11Cl2N3S. Calculated: % C, 56.20; % 
H, 3.88; % N, 11.57; found % C, 55.94; % H, 3.59; % N, 11.83 
 
4.1.5. General synthetic procedures for 8-Substituted-2-(p-substituted-Benzylamino)-5H-
benzothiopyrano[4,3-d]pyrimidines 3a-i  
The appropriate benzylguanidine sulfate 6a-c (1.70 mmoles) was added, at room 
temperature, under nitrogen atmosphere, to a stirred solution of sodium ethoxide (0.059 g, 
2.55 mmoles of sodium in 8 mL of anhydrous ethanol). The resulting suspension was 
stirred at room temperature for 15 minutes, then the appropriate dimethylaminomethylene 
derivative 1a-c (0.187 g, 0.85 mmoles) was added, and the reaction mixture was refluxed 
for 6 hours. After cooling, the suspension was concentrated under reduced pressure. The 
residue obtained was washed with water and collected, to give crude pyrimidines 3a-i, 
which were purified by recrystallization from ethanol. 
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4.1.5.1. 2-Benzylamino-5H-benzothiopyrano[4,3-d]pyrimidine (3a). Yield: 20%; M. p. 
144-146 °C; 1H NMR (400 Hz, DMSOd6):  3.92 (s, 2H, CH2S); 4.56 (d, 2H, CH2NH, J = 
6.4 Hz) 7.16-7.39 (m, 8H, 7-, 8-, 9-, 2'-, 3'-, 4'-, 5', 6'-ArH) 7.81 (t, 1H, CH2NH exch. J = 
6.3 Hz); 8.19 (d, 1H, 10-ArH, J = 7.6 Hz); 8.26 (s, 1H, 4-ArH). 13C NMR (400 Hz, 
DMSOd6): 25.93, 44.18, 126.00, 126.47, 126.89, 127.11, 127.74, 128.24, 130.82, 140.59, 
161.80. Elemental analysis for C18H15N3S. Calculated: % C, 70.79; % H, 4.95; % N, 13.76; 
found % C, 70.52; % H, 4.77; % N, 13.99 
 
4.1.5.2. 2-(p-Methoxy-benzylamino-5H-benzothiopyrano[4,3-d]pyrimidine (3b). Yield: 
25%; M. p. 160-162 °C; 1H NMR (400 Hz, DMSOd6):  3.70 (S, 3H, -OCH3); 3.92 (s, 2H, 
CH2S); 4.48 (d, 2H, CH2NH, J = 6.2 Hz) 6.85-(d, 2H, 2',6'-ArH, J = 8.4 Hz); 7.26-7.39 (m, 
5H, 7-, 8-, 9-, 3',5'-ArH); 7.71 (t, 1H, CH2NH exch., J = 6.3 Hz); 8.20-8.25 (m, 2H, 10-, 4-
ArH). 13C NMR (100 Hz, DMSOd6): 25.88, 43.57, 54.94, 113.52, 125.97, 126.86, 
127.70, 128.39, 130.76, 132.43, 157.98, 161.73. Elemental analysis for C19H17N3OS. 
Calculated: % C, 68.03; % H, 5.11; % N, 12.53; found % C, 67.78; % H, 5.32; % N, 12.67 
 
4.1.5.3. 2-(p-Chloro-benzylamino-5H-benzothiopyrano[4,3-d]pyrimidine (3c). Yield: 31%; 
M. p. 152-154 °C; 1H NMR (400 Hz, DMSOd6):  3.92 (s, 2H, CH2S); 4.53 (d, 2H, 
CH2NH, J = 6.0 Hz); 7.28-7.39 (m, 7H, 7-, 8-, 9-, 2',6'-, 3',5'-ArH); 7.82 (t, 1H, CH2NH 
exch., J = 5.9 Hz); 8.17 (d, 1H, 10-ArH, J = 7.2 Hz); 8.26 (s, 1H, 4-ArH). 13C NMR (100 
Hz, DMSOd6): 25.90, 43.62, 126.02, 126.89, 127.75, 128.09, 128.09, 130.86, 139.69. 
Elemental analysis for C18H14ClN3S. Calculated: % C, 63.62; % H, 4.15; % N, 12.36; 
found % C, 63.39; % H, 4.27; % N, 12.07 
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4.1.5.4. 8-Methoxy-2-benzylamino-5H-benzothiopyrano[4,3-d]pyrimidine (3d). Yield: 
12%; M. p. 167-169 °C; 1H NMR (400 Hz, DMSOd6):  3.80 (S, 3H, 8-OCH3); 3.91 (s, 
2H, CH2S); 4.54 (d, 2H, CH2NH, J = 6.4 Hz); 6.87-6.92 (m, 2H, 7-, 9-ArH); 7.19-7.33 (m, 
5H, 2'-, 3'-, 4'-, 5', 6'-ArH); 7.72 (t, 1H, CH2NH exch. J = 6.3 Hz); 8.13 (d, 1H, 10-ArH, J 
= 8.8 Hz); 8.19 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.18, 44.17, 55.48, 
111.98, 112.73, 126.43, 127.09, 128.12, 140.67. Elemental analysis for C19H17N3OS. 
Calculated: % C, 68.03; % H, 5.11; % N, 12.53; found % C, 67.96; % H, 5.18; % N, 12.61 
 
4.1.5.5. 8-Methoxy-2-(p-methoxy-benzylamino)-5H-benzothiopyrano[4,3-d]pyrimidine 
(3e). Yield: 25%; M. p. 140-142 °C; 1H NMR (400 Hz, DMSOd6):  3.70 (S, 3H, 4'-
OCH3); 3.80 (S, 3H, 8-OCH3); 3.90 (s, 2H, CH2S); 4.46 (d, 2H, CH2NH, J = 6.0 Hz) 6.85-
(d, 2H, 2',6'-ArH, J = 8.4 Hz); 6.90 (d, 1H, 9-ArH, J = 9.8); 6.92 (s, 1H, 7-ArH); 7.27 (d, 
2H, 3',5'-ArH, J = 8.4 Hz); 7.62 (t, 1H, CH2NH exch., J = 6.0 Hz); 8.15 (d, 1H, 10-ArH, J 
= 9.8 Hz); 8.18 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.18, 43.89, 54.93, 
55.58, 111.23, 111.35, 112.08, 114.17, 118.67, 124.18, 130.51, 132.23, 138.05, 158.61, 
159.73, 159.92, 160.83, 164.41. Elemental analysis for C20H19N3O2S. Calculated: % C, 
64.94; % H, 4.88; % N, 11.96; found % C, 65.19; % H, 4.69; % N, 12.27 
 
4.1.5.6. 8-Methoxy-2-(p-chloro-benzylamino)-5H-benzothiopyrano[4,3-d]pyrimidine (3f). 
Yield: 29%; M. p. 170-172 °C; 1H NMR (400 Hz, DMSOd6):  3.80 (S, 3H, OCH3); 3.91 
(s, 2H, CH2S); 4.52 (d, 2H, CH2NH, J = 6.4 Hz); 6.85-6.93 (m, 2H, 7-, 9-ArH); 7.36-7.42 
(m, 4H, 2',6'-, 3',5'-ArH); 7.74 (t, 1H, CH2NH exch., J = 6.3 Hz); 8.11 (d, 1H, 10-ArH); 
8.19 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.11, 43.60, 55.50, 112.00, 112.76, 
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128.07, 128.53, 128.94, 130.93, 161.05. Elemental analysis for C19H16ClN3OS. Calculated: 
% C, 61.70; % H, 4.36; % N, 11.36; found % C, 61.99; % H, 4.17; % N, 10.98 
 
4.1.5.7. 8-Chloro-2-benzylamino-5H-benzothiopyrano[4,3-d]pyrimidine (3g). Yield: 14%; 
M. p. 158-160 °C; 1H NMR (400 Hz, DMSOd6):  3.96 (s, 2H, CH2S); 4.55 (d, 2H, 
CH2NH, J = 6.2 Hz) 7.19-7.39 (m, 6H, 9-, 2'-, 3'-, 4'-, 5', 6'-ArH); 7.51 (d, 1H, 7-ArH, J = 
1.8 Hz); 7.86 (t, 1H, CH2NH exch. J = 6.4 Hz); 8.17 (d, 1H, 10-ArH); 8.27 (s, 1H, 4-ArH). 
13C NMR (100 Hz, DMSOd6): 25.89, 44.17, 126.07, 126.48, 126.95, 127.10, 128.12, 
128.40, 135.35, 140.46, 161.77. Elemental analysis for C18H14ClN3S. Calculated: % C, 
63.62; % H, 4.15; % N, 12.36; found % C, 63.89; % H, 3.99; % N, 12.22 
 
4.1.5.8. 8-Chloro-2-(p-methoxy-benzylamino)-5H-benzothiopyrano[4,3-d]pyrimidine (3h). 
Yield: 13%; M. p. 165-167 °C; 1H NMR (400 Hz, DMSOd6):  3.33 (S, 3H, 4'-OCH3); 
3.95 (s, 2H, CH2S); 4.48 (d, 2H, CH2NH, J = 6.2 Hz) 6.86 (d, 2H, 2',6'-ArH, J = 8.8 Hz); 
7.28 (d, 2H, 3',5'-ArH, J = 9.0 Hz); 7.37-7.42 (dd, 1H, 9-ArH, J9-10 = 8.9 Hz, J9-7 = 2.0 
Hz); 7.51 (d, 1H, 7-ArH, J9-7 = 2.0 Hz); 7.76 (t, 1H, CH2NH exch. J = 6.2 Hz); 8.21 (d, 1H, 
10-ArH, J = 8.9 Hz); 8.27 (s, 1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.22, 43.94, 
55.56, 114.18, 117.17, 118.64, 125.71, 128.52, 129.13, 130.53, 132.24, 133.46, 159.72, 
159.91, 164.43.  Elemental analysis for C19H16ClN3OS. Calculated: % C, 61.70; % H, 4.36; 
% N, 11.36; found % C, 62.09; % H, 4.17; % N, 11.61 
 
4.1.5.9. 8-Chloro-2-(p-chloro-benzylamino)-5H-benzothiopyrano[4,3-d]pyrimidines (3i). 
Yield: 12%; M. p. 185-187 °C; 1H NMR (400 Hz, DMSOd6):  3.97 (s, 2H, CH2S); 4.54 
(d, 2H, CH2NH, J = 6.4 Hz) 7.34-7.40 (m, 5H, 2',6'-, 3',5'-, 9-ArH); 7.51 (d, 1H, 7-H, J = 
2.2 Hz); 7.87 (t, 1H, CH2NH exch. J = 6.4 Hz); 8.17 (d, 1H, 10-ArH, J = 8.8 Hz); 8.28 (s, 
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1H, 4-ArH). 13C NMR (100 Hz, DMSOd6): 26.23, 43.92, 117.15, 118.61, 125.72, 128.63, 
129.34, 132.37, 133.45, 138.02, 138.47, 159.71, 159.93, 164.42. Elemental analysis for 
C18H13Cl2N3S. Calculated: % C, 57.76; % H, 3.50; % N, 11.23; found % C, 58.04; % H, 
3.71; % N, 10.97 
 
4.2. Biological evaluation 
 
4.2.1. In vitro assay for VEGFR-2 activity 
The VEGFR-2 kinase assay has been performed by using the recombinant human 
enzyme (Life technologies) and the fluorescence peptide substrate-based assay Omnia Tyr 
Peptide 8 (Invitrogen). Briefly, 15 L of reaction mixture containing kinase reaction 
buffer, 1 mM ATP, 0.2 mM DTT and Omnia Peptide Substrate as indicated by the 
manufacturer was incubated at 30 °C for 5 min in 96-well microtiter plates. After addition 
of VEGFR-2 the samples (final volume of 20 L) were incubated for further 50 min in the 
absence (control) or in the presence of different concentrations of test compounds and 
during incubation the fluorescence intensity (λex = 355 nm, λem = 460 nm) was recorded on 
a Victor 1460 Multilabel counter (Perkin Elmer). 
 
4.2.2. Inhibition growth assay 
HeLa (human cervix adenocarcinoma cells) and A-431 (skin carcinoma squamous 
cells) were grown in Nutrient Mixture F-12 [HAM] (Sigma Chemical Co.) and Dulbecco’s 
modified Eagle’s medium (Sigma Chemical Co.) respectively, supplemented with 10% 
heat-inactivated fetal calf serum (Invitrogen). MSTO-211H (human biphasic mesothelioma 
cells) were grown in RPMI 1640 (Sigma Chemical Co.) supplemented with 2.4 g/L Hepes, 
0.11 g/L Na-pyruvate and 10% heat-inactivated fetal calf serum (Invitrogen). 100 U/mL 
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penicillin, 100 g/mL streptomycin and 0.25 g/mL amphotericin B (Sigma Chemical Co.) 
were added to the media. HUVECs (human umbilical vein endothelian cells) were 
purchased from Lonza Ltd. and maintained as recommended. The cells were cultured at 37 
°C in a moist atmosphere of 5% carbon dioxide in air. 
Cells (3-4x104)  were seeded into each well of a 24-well cell culture plate. After incubation 
for 24 h, various concentrations of the test agents were added. The cells were then 
incubated in standard conditions for a further 72 h. 
A trypan blue assay was performed to determine cell viability. Cytotoxicity data were 
expressed as GI50 values, i.e., the concentration of the test agent inducing 50% reduction in 
cell number compared with control cultures. 
 
4.2.3. Phospho-VEGFR-2 inhibition assay 
HUVECs (2x105 cells/well) were seeded and maintained in 1% FBS medium. After 24 
h, cells were treated for 72 h with 2b, 2e and 2i at a concentration corresponding to the 
experimental GI50 of cell proliferation, at a higher concentration (2.5 µM) and at a lower 
concentration (0.1 µM), or with vehicle alone. The DMSO concentration in control’s 
media was the one used to dilute the highest concentration of the compound in the same 
experiment. The media were supplemented with rhVEGF (10 ng/mL). At the end of the 
experiment, the media was removed, the cells were rinsed with ice-cold PBS and directly 
lysed with 0.5 mL of ice-cold 1X lysis buffer (20 mM Tris pH7.5, 150 mM, 1 mM EDTA, 
1 mM EGTA, 1% triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerolphosphate, 1mM Na3VO4, 1 µg/mL leupetin; Cell Signaling Technology, MA, 
USA, cat.#9803) and 1 mM PMSF to each plate for 5 min at 4 °C. Lysates were collected 
and sonicated on ice for 10 s. The samples were microcentrifuged for 10 min at 4 °C and 
the supernatant was collected. Endothelial cell lysates were assayed as per the 
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manufacturer’s instructions with PathScan phospo-VEGFR-2 (Tyr1175) and with the Total 
VEGFR-2 sandwich ELISA kits (Cell Signaling Technology). The optical density was 
determined using a Multiskan Spectrum microplate reader (Thermo Labsystems, Milan, 
Italy) set to 450 nm. All experiments were repeated, independently, three times with at 
least 9 samples for each drug concentration. 
 
4.2.4. Ex vivo “rat aortic ring” assay 
The assay was performed with some modifications of the method originally reported 
by Nicosia and Ottinetti.[35] The artery was dissected from the aortic arch to the 
diaphragm, and the periaortic fibroadipose tissue was carefully removed keeping it in a 
Petri dish with nutrient Krebs solution (NaCl 118 mM, KCl 4.7 mM, CaCl2 1.8 mM, 
KH2PO4 1.2 mM, NaHCO3 25.0 mM, glucose 11.0 mM). One-millimetre length aortic 
rings were sectioned, transferred to a small Petri plate containing Endothelial cell basal 
medium MV2, (EBM MV2, Promocell, Heidelberg, Germany), and antibiotics (gentamicin 
30µg/mL, amphotericin 0.015µg/mL), to avoid possible contamination. The assay was 
performed in a 96-well flat-bottomed plate, which was kept on ice until use. All the 
materials that come in contact with Matrigel would be cold in order to prevent its 
solidification, which takes place at room temperature. Likewise, Matrigel was kept on ice 
in cold chamber (4 °C), for at least 4 hours before the experiment took place. 50 µL of 
Matrigel per well were added, and the aortic rings were randomized into wells. After 15 
minutes at room temperature Matrigel polymerized, and 200 µL of EBM MV2 growth 
medium, preheated to 37 °C, were added. Finally 20 µL of the drug, whose effect is 
intended to be studied, were added to the appropriate wells. The plate was incubated at 37 
°C and 5% CO2 for 7 days, renewing the medium, as well as the stimuli required the day 
after starting the experiment, and every two days.  
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4.2.5. Image acquisition 
To daily monitoring the new vessels growth, cultures were daily photographed (days 
3–7) on an inverted microscope Leica DM IL LED with a Leica Camera (objective 2.5x) 
and analyzed by Leica Microsystems LAS Software V3.7.0 (Heerbrugg Switzerland). To 
determine the growth kinetic, it was measured in microns the distance in the x and y axis, 
taking as point source, in each case, the outer surface of the ring (Figure 6A). The mean of 
x and y values indicate the angiogenic growth for each aortic explant. In addition, on the 
7th day, a final time fluorescence cell staining was also performed. For this purpose, 1µL 
of calcein (Molecular Probes Inc. InvitrogenTM Paisley, UK) was added, and after 
incubating for 15 minutes, the images were visualized using a Nikon fluorescence 
microscope Eclipse E800 equipped with Nikon camera, (4x objective) and captured using 
the software Nikon ACT-1 (Figure 6B). 
 
 
Figure 6. Visualization of the angiogenic growth: (A) at day 3 (Leica DM IL LED Leica 
camera, 2.5x objective). (B) Fluorescence cell staining at day 7 (Nikon fluorescence 
microscope Eclipse E800 equipped with Nikon camera, 4x objective). 
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4.2.6. In vitro EGFR Inhibition Assay 
The inhibitory activity of the test compounds was assayed by adding 5 µL of the 
inhibitor solution to the reaction mixture described above. All the products were dissolved 
in 100% DMSO and diluted to the appropriate concentrations with Tyrosine Kinase 
Reaction Buffer, provided by the kit. Final concentration of DMSO in assays solutions 
never exceed 1%,, and proved to have no effects on protein activity. Determination of the 
IC50 values was performed by linear regression analysis of the log-dose response curve, 
which was generated using at least five concentrations, between 100 M and 10 nM, of the 
inhibitor causing an inhibition between 20% and 80%, with two replicates at each 
concentration. Gefitinib (IC50 = 0.022 μM) was exploited as the reference standard. The 
95% confidence limits (95% CL) were calculated from t values for n - 2, where n is the 
total number of determinations (Table 3). Tests were performed at 30 °C in 96-well 
microtiter plates, exploiting the Omnia Tyr Peptide 7 Kit (Invitrogen). Briefly, 5 µL of 3 
mU/L EGFR was added to a reaction mixture containing 5 µL of Tyrosine Kinase, 
Reaction Buffer, 5 µL of Tyrosine Kinase Substrate, 5 µL of 1 mM ATP, 5µL of 1 mM 
DTT, 25 µL of ultrapure water and the reaction was monitored with the fluorescence meter 
Victor3™ PerkinElmer at 360 nm (excitation) and 485 nm (emission). Kinase activity of 
the target protein was calculated from a linear least-squares fit of the data for fluorescence 
intensity versus time. 
 
4.2.7. In vitro Kinases Enzymatic Inhibition 
The screening of compounds 1d, 2b and 2i on a set of 10 human kinases 
(Akt1/PKB, AurA/Aur2 kinase, CDC2/CDK1, ERK1, FAK, MEK1/MAP2K1, PDGFR 
kinase, RAF-1 kinase, ROCK1, Src kinase) was performed by CEREP (France), 
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according to the company’s standard operating procedures, (Figures 4a-c, Tables 
S1a,b). 
 
4.3. Molecular Modelling 
 
The new version of the docking program AutoDock (version 4.2, AD4) [69,70], as 
implemented through the graphical user interface called AutoDockTools (ADT), was used 
to perform cross-docking experiments on the VEGFR-2 X-ray structures having PDB 
codes: 1YWN, 2P2H, 2XIR, 3BE2, 3EWH, 3VHE, 3VNT, 3VO3, 4AG8, 4ASE. These 
structure were prepared using the Protein Preparation Wizard in Maestro (Protein 
Preparation Wizard, Schrödinger, LLC, New York, NY), which assigns bond orders, adds 
hydrogen atoms, deletes water molecules, and generates appropriate protonation states. 
Maestro was also used to superimpose all the complexes on the 1YWN structure. 
The ligand and the receptor structures were then converted to AD4 format files using ADT 
generating automatically all other atom values. The docking area was centered on the 
putative binding site. A set of grids of 60 Å × 60 Å × 60 Å with 0.375 Å spacing was 
calculated around the docking area for the ligand atom types using AutoGrid4. For each 
ligand, 200 separate docking calculations were performed. Each docking calculation 
consisted of 10 million energy evaluations using the Lamarckian genetic algorithm local 
search (GALS) method. The GALS method evaluates a population of possible docking 
solutions and propagates the most successful individuals from each generation into the 
subsequent generation of possible solutions. A low-frequency local search according to the 
method of Solis and Wets is applied to docking trials to ensure that the final solution 
represents a local minimum. All dockings described in this paper were performed with a 
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population size of 250, and 300 rounds of Solis and Wets local search were applied with a 
probability of 0.06. A mutation rate of 0.02 and a crossover rate of 0.8 were used to 
generate new docking trials for subsequent generations, and the best individual from each 
generation was propagated over the next generation. The docking results from each of the 
200 calculations were clustered on the basis of root-mean square deviation (rmsd) 
(solutions differing by less than 1.5 Å) between the Cartesian coordinates of the atoms and 
were ranked on the basis of free energy of binding (ΔGAD4).  
Compound 2b was then built using the builder in the Maestro package of Schroedinger 
Suite 2007 and optimized using a version of MacroModel also included. The 4AG8 energy 
grids calculated for the cross-docking experiments were also used to perform AD4 
calculations of 2b employing the docking parameters described above. Because AD4 does 
not perform any structural optimization and energy minimization of the complexes found, 
a molecular mechanics/energy minimization (MM/EM) approach was applied to refine the 
AD4 output. The computational protocol applied consisted of the application of 100000 
steps of the Polak−Ribiére conjugate gradients (PRCG) or until the derivative convergence 
was 0.05 kJ/mol.  
 
Supporting Information available 
Supplementary data (Tables S1a, S1b including CEREP screening results of compounds 
1d, 2b and 2i) associated with this article can be found in the online version. 
 
Abbreviation used 
VEGF, Vascular Endothelial Growth Factor; VEGFR, Vascular Endothelial Growth Factor 
Receptor; KDR, human kinase insert domain receptor; EGFR, Epidermal Growth Factor 
Receptor; HUVEC, human umbilical vein endothelial cell; HeLa, cervix adenocarcinoma 
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cell lines; A-431, epidermoid carcinoma cell lines; MSTO-211H, biphasic mesothelioma 
cell lines; RTK, Receptor Tyrosine Kinase. 
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